Trial · NCT04524390
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change in Total Serum Bilirubin Levels | Double Blind - Maralixibat | -3.5 | Standard Error 0.853 | mg/dl | |
| Mean Change in Total Serum Bilirubin Levels | Double Blind - Placebo | -3.11 | Standard Error 0.947 | mg/dl | |
| Mean Change in Total Serum Bile Acids | Double Blind - Maralixibat | -51.19 | Standard Error 24.436 | umol/L | |
| Mean Change in Total Serum Bile Acids | Double Blind - Placebo | -5.29 | Standard Error 28.440 | umol/L | |
| Proportion of Participants With Mean TSB Levels <2 mg/dL Through Week 26 | Double Blind - Maralixibat | 24 | Participants | ||
| Proportion of Participants With Mean TSB Levels <2 mg/dL Through Week 26 | Double Blind - Placebo | 20 | Participants | ||
| Proportion of Participants Observed to Have a Liver-related Clinical Event Transplantation, Liver Decompensation, Discontinuations Due to Liver Related Events, or Death. | Double Blind - Maralixibat | 8 | Participants | ||
| Proportion of Participants Observed to Have a Liver-related Clinical Event Transplantation, Liver Decompensation, Discontinuations Due to Liver Related Events, or Death. | Double Blind - Placebo | 7 | Participants | ||
| Proportion of Participants Undergoing Liver Transplantation or Death | Double Blind - Maralixibat | 5 | Participants | ||
| Proportion of Participants Undergoing Liver Transplantation or Death | Double Blind - Placebo | 3 | Participants | ||
Proportion of Participants Observed to Develop Clinically Evident Portal Hypertension Defined as Splenomegaly and Thrombocytopenia (Platelet Count <150 x 109/L) or Clinically Evident Ascites or Endoscopic Evidence of Esophageal or Gastric Varices. | Double Blind - Maralixibat | 3 | Participants | ||
Proportion of Participants Observed to Develop Clinically Evident Portal Hypertension Defined as Splenomegaly and Thrombocytopenia (Platelet Count <150 x 109/L) or Clinically Evident Ascites or Endoscopic Evidence of Esophageal or Gastric Varices. | Double Blind - Placebo | 4 | Participants | ||
| Proportion of Participants With Mean TSB Levels ≤1.2 mg/dL | Double Blind - Maralixibat | 23 | Participants | ||
| Proportion of Participants With Mean TSB Levels ≤1.2 mg/dL | Double Blind - Placebo | 18 | Participants | ||
| Proportion of Participants With Mean sBA Levels ≤40 mmol/L | Double Blind - Maralixibat | 10 | Participants | ||
| Proportion of Participants With Mean sBA Levels ≤40 mmol/L | Double Blind - Placebo | 7 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04524390/results